Cancer Res: New Ideas for Immunological Treatment for Gastric Cancer
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On March 10, 2020, Gao Weiqiang of Shanghai Jiaotong University's School of Biomedical Engineering and Ma Bin's team published their research on "Blockade of beta-catenin-induced CCL28 of the Gastric cancer progression of Treg cell inindinThe first authors of the study were Ph.Dgraduate student Yu Lu, Professor Gao Weiqiang and Associate Researcher Ma Bin as co-authorsthe immunotreatment of stomach cancer is very difficult, after several studies have failedstomach cancer is a type of tumor with very high incidence and fatality rate in East Asian countries dominated by ChinaThe incidence of stomach cancer in China accounts for 40% of the world's total, and the mortality rate is 4 to 8 times that of developed countries in Europe and americaHelicobacter pylori infections, diet, smoking, and environmental factors may all increase the risk of stomach cancerresearch in the field of tumor immunity has rapidly promoted the development of immunotherapy in recent yearsWnt/beta-cateninis is one of the most common cancer-causing pathways in stomach cancer, which directly promotes the proliferation of tumor cells and slows tumor cell apoptosis, but its regulatory effect on the immune microenvironment of gastric tumors is not clearThe researchers found that abnormal activation of beta-catenin signals in stomach cancer caused the expression of the chemokine CCL28 and the increase in leaching of T-cells, revealing the immune inhibitory of the beta-catenin pathwayThis study extends previous understanding of the carcinogenic effects of the Wnt/beta-catenin pathway, which is mainly dependent on its regulation of the proliferation, survival and differentiation of gastric cancer cells, and confirms that the immunomodulation function of the beta-catenin signaling pathway also plays an important role in tumor progressionWhat's more, blocking the leaching of T-cells by targeting the trending factor CCL28 provides new ideas for immunotherapy for stomach cancerAuthor: Shanghai Jiaotong University Source:of Shanghai Jiaotong University
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.